BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 10945157)

  • 1. [Open studies in comparison to controlled studies in testing of neuroleptics].
    Pajonk FG; Holzbach R; Naber D
    Fortschr Neurol Psychiatr; 2000 Jul; 68(7):313-20. PubMed ID: 10945157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the efficacy of atypical antipsychotics in open uncontrolled versus double-blind controlled trials in schizophrenia.
    Pajonk FG; Holzbach R; Naber D
    Psychopharmacology (Berl); 2002 Jun; 162(1):29-36. PubMed ID: 12107614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
    Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
    Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double blind research].
    Bures E; Pöldinger W
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():45-52. PubMed ID: 35479
    [No Abstract]   [Full Text] [Related]  

  • 8. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
    Taylor DM; Smith L
    Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Citalopram in patients with unsatisfactory response to neuroleptics: an open follow-up study.
    Syvälahti EK; Kallioniemi H; Lehto H
    Methods Find Exp Clin Pharmacol; 1994; 16(1):49-55. PubMed ID: 7909349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The behavioral toxicity of bromocriptine in patients with psychiatric illness.
    Perovich RM; Lieberman JA; Fleischhacker WW; Alvir J
    J Clin Psychopharmacol; 1989 Dec; 9(6):417-22. PubMed ID: 2574194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
    Paleacu D; Barak Y; Mirecky I; Mazeh D
    Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study.
    Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Dec; 255(6):371-2. PubMed ID: 16382376
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF
    Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol.
    den Boer JA; Westenberg HG
    Psychopharmacol Bull; 1990; 26(1):99-107. PubMed ID: 1973547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New anxiolytic drugs: methodological issues].
    Ginestet D; Corruble E
    Encephale; 1993; 19(6):627-37. PubMed ID: 12404782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania.
    Sussman N; Mullen J; Paulsson B; Vågerö M
    J Affect Disord; 2007; 100 Suppl 1():S55-63. PubMed ID: 17383736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse prevention in schizophrenia: evidence from longterm, randomized, double-blind clinical trials.
    Pecenak J
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():49-70. PubMed ID: 17262007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
    Meltzer HY; Sommers AA; Luchins DJ
    J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.